Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on antiretroviral therapy (ART), with trial start and first patient visit expected in November 2024.</li><li>The single-site, double-blind study will enroll 40 subjects, randomized 3:1 to Veldona or placebo.</li><li>The primary endpoint is the proportion of patients achieving &gt;75% reduction in oral warts surface area at 24 weeks, with secondary endpoints of &gt;50% reduction and patient- and physician-assessed quality of oral health. </li></ul>

Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on antiretroviral therapy (ART), with trial start and first patient visit expected in November 2024.The single-site, double-blind study will enroll 40 subjects, randomized 3:1 to Veldona or placebo.The primary endpoint is the proportion of patients achieving &gt;75% reduction in oral warts surface area at 24 weeks, with secondary endpoints of &gt;50% reduction and patient- and physician-assessed quality of oral health. 

Ainos, Inc. -  Veldona Oral Warts Trial to Start in Taiwan Before Year-End